Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chunxia Su

Showing results (201-210 of 223) with videos related to

Pageof 23
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 25, 2023
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLCLei Wang, Yongzhong Luo, Shengxiang Ren, et al.
Translational Lung Cancer Research|September 22, 2016
From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert PanelChunxia Su, Mathias Meyer, Robert Pirker, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2019
Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLCShuo Yang, Shiqi Mao, Xuefei Li, et al.
Cancer Immunology, Immunotherapy : CII|September 20, 2022
Correction to: The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center studyChongwu Li, Junqi Wu, Long Jiang, et al.
Cancer Immunology, Immunotherapy : CII|September 3, 2022
The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center studyChongwu Li, Junqi Wu, Long Jiang, et al.
Translational Lung Cancer Research|March 15, 2021
Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutationsShuo Yang, Yan Wang, Chao Zhao, et al.
International Journal of Surgery (London, England)|September 27, 2023
Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort studyHongsheng Deng, Juan Zhou, Hualin Chen, et al.
Theranostics|December 1, 2017
Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLCTao Jiang, Xuefei Li, Jianfei Wang, et al.
Chinese Medical Journal|March 15, 2023
Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutationShiqi Mao, Libo Luo, Shuo Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2019
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II TrialJianming Xu, Jie Li, Chunmei Bai, et al.
Pageof 23

Showing results (201-210 of 223) with videos related to

Sort By:
Pageof 23
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 25, 2023
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLCLei Wang, Yongzhong Luo, Shengxiang Ren, et al.
Translational Lung Cancer Research|September 22, 2016
From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert PanelChunxia Su, Mathias Meyer, Robert Pirker, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2019
Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLCShuo Yang, Shiqi Mao, Xuefei Li, et al.
Cancer Immunology, Immunotherapy : CII|September 20, 2022
Correction to: The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center studyChongwu Li, Junqi Wu, Long Jiang, et al.
Cancer Immunology, Immunotherapy : CII|September 3, 2022
The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center studyChongwu Li, Junqi Wu, Long Jiang, et al.
Translational Lung Cancer Research|March 15, 2021
Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutationsShuo Yang, Yan Wang, Chao Zhao, et al.
International Journal of Surgery (London, England)|September 27, 2023
Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort studyHongsheng Deng, Juan Zhou, Hualin Chen, et al.
Theranostics|December 1, 2017
Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLCTao Jiang, Xuefei Li, Jianfei Wang, et al.
Chinese Medical Journal|March 15, 2023
Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutationShiqi Mao, Libo Luo, Shuo Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2019
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II TrialJianming Xu, Jie Li, Chunmei Bai, et al.
Pageof 23